Natera Inc. ( (NTRA) ) has released its Q3 earnings. Here is a breakdown of the information Natera Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Natera Inc. is a global leader in cell-free DNA and precision medicine, focusing on oncology, women’s health, and organ health, with a commitment to integrating personalized genetic testing into standard healthcare practices. In its third-quarter 2025 earnings report, Natera announced a significant revenue increase to $592.2 million, marking a 34.7% rise from the previous year, driven by a 35.3% growth in product revenues. The company also processed 893,600 tests, a 15.2% increase from the same quarter in 2024, with oncology tests showing a notable 53.9% growth. Natera’s gross margin improved to 64.9%, up from 61.8% the previous year, reflecting higher revenues and cost efficiencies. Despite these gains, the company reported a net loss of $87.5 million, or $0.64 per share, compared to a $31.6 million loss in the same period last year. Looking ahead, Natera has raised its 2025 annual revenue guidance, anticipating total revenues between $2.18 billion and $2.26 billion, and continues to focus on innovation and expanding its product offerings.